Publications by authors named "Mark Moasser"

Claim this Profile
M
Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer.
Roos Vincken, Samuel T Pasco, Veronica Steri, Laura Bozal-Basterra, Wilfred F J van IJcken, Mark M Moasser

Biomed Pharmacother· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.
Julia Ye, Nadine Goldhammer, Poonam Vohra, Shruti Warhadpande, George C de Castro, Mark M Moasser

Cancer Cytopathol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer.
Laura A Huppert, Amelia S Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Mark Moasser

NPJ Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Ozge Gumusay, Laura A Huppert, Mark Jesus M Magbanua, Chiara A Wabl, Michael Assefa, Mark Moasser

Breast Cancer Res Treat· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.
Kanwal P S Raghav, Mark M Moasser

Clin Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF colorectal tumors.
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Bo Pan, Courtney A Dreyer, Mark M Moasser

Nat Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, Elliott Peterson, Veronica Steri, Mark M Moasser

Cell Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
Mark M Moasser

Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Erica S Tsang, Rahul R Aggarwal, Mallika S Dhawan, Emily K Bergsland, Edwin A Alvarez, Mark M Moasser

Cancer Res Commun· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Chi-Heng Wu, Linlin Wang, Chen-Yen Yang, Kwun Wah Wen, Brian Hinds, Mark Moasser

Blood Adv· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.
Marcia R Campbell, Ana Ruiz-Saenz, Elliott Peterson, Christopher Agnew, Pelin Ayaz, Mark M Moasser

Cell Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, Elliott Peterson, Veronica Steri, Mark M Moasser

Cell Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid.
Neelima Vidula, Sally Greenberg, Laura Petrillo, Jimmy Hwang, Michelle Melisko, Mark Moasser

NPJ Breast Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of CDCP1 triggers FAK activation in detached prostate cancer cells.
Sara G Pollan, Pai-Chi Teng, Yu Jen Jan, Julie Livingstone, Cai Huang, Mark Moasser

Am J Clin Exp Urol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.
Ana Ruiz-Saenz, Farima Zahedi, Elliott Peterson, Ashley Yoo, Courtney A Dreyer, Mark M Moasser

Mol Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Avisek Majumder, Manbir Sandhu, Debarko Banerji, Veronica Steri, Adam Olshen, Mark M Moasser

Sci Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression and purification of active human kinases using Pichia pastoris as a general-purpose host.
May H Abdel Aziz, Yao Fan, Lijun Liu, Mark M Moasser, Haian Fu

Protein Expr Purif· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Chi-Heng Wu, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Taha Rakhshandehroo, Mark Moasser

J Invest Dermatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.
Soheila Kazemi, Shinsaku Kawaguchi, Christian E Badr, Daphne R Mattos, Ana Ruiz-Saenz, Mark M Moasser

Biochem Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER family in cancer progression: From discovery to 2020 and beyond.
Rakesh Kumar, Bijesh George, Marcia R Campbell, Nandini Verma, Aswathy Mary Paul, Mark M Moasser

Adv Cancer Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J Chien

Nat Commun· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.
Jean-Philippe Coppé, Miki Mori, Bo Pan, Christina Yau, Denise M Wolf, Mark M Moasser

Nat Cell Biol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src.
Danislav S Spassov, Ana Ruiz-Saenz, Amit Piple, Mark M Moasser

Cell Rep· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
Ana Ruiz-Saenz, Courtney Dreyer, Marcia R Campbell, Veronica Steri, Nate Gulizia, Mark M Moasser

Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of inside-out β1-integrin activation by CDCP1.
Sara G Pollan, Fangjin Huang, Jamie M Sperger, Joshua M Lang, Colm Morrissey, Mark M Moasser

Oncogene· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis